The Global Health Policy Center leads CSIS’s research bridging foreign policy and public health communities.

Sign and logo of the Center William Rappard, home of the World Trade Organization (WTO)

TRIPS Waivers and Pharmaceutical Innovation

TRIPS waivers undermine the U.S. pharmaceutical industry by degrading the IP protections which are essential to the pharmaceutical innovation ecosystem. Less innovation in the pharmaceutical industry means fewer vaccines and drugs in the future, leaving the United States and other nations less prepared for future pandemics and other health emergencies.

Blog Post by Christopher Borges — March 15, 2023

Past Events

Related Programs


Katherine E. Bliss
Senior Fellow and Director, Immunizations and Health Systems Resilience, Global Health Policy Center